What is HC Wainwright’s Forecast for XBIO FY2026 Earnings?

Xenetic Biosciences Inc (NASDAQ:XBIO) – Equities research analysts at HC Wainwright issued their FY2026 earnings per share estimates for Xenetic Biosciences in a report released on Monday, November 11th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($0.64) for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Xenetic Biosciences’ current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Xenetic Biosciences’ FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.75) EPS.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 47.21%. The business had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.75 million.

Xenetic Biosciences Stock Up 0.3 %

Xenetic Biosciences stock opened at $3.66 on Thursday. Xenetic Biosciences has a 12-month low of $2.78 and a 12-month high of $5.20. The business’s 50-day moving average price is $3.89 and its two-hundred day moving average price is $3.93. The stock has a market cap of $5.64 million, a PE ratio of -1.38 and a beta of 2.25.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.